Update: Promising data from Actimab-A Phase I/II study
Actinium Pharmaceuticals is progressing two compounds, Iomab-B and Actimab-A, through the clinic for the treatment of blood cancers, with a further three programmes in preclinical development. Actimab-A has successfully completed Cohort 3 of the first part of the Phase I/II trial underway in elderly patients with newly diagnosed AML. The encouraging clinical outcomes, coupled with a promising toxicity profile, suggest it should progress to Phase II once the maximum dose is established.Actinium Pharmaceuticals is a clinical-stage, biopharmaceutical company focused on developing and potentially commercializing therapies for targeted conditioning prior to cell therapies. The company's key targeted conditioning product candidate is Iomab-B, an Antibody Radiation-Conjugates (ARC) that is comprised of the anti-CD45 mAb known as apamistamab or BC8 and the radioisotope iodine-131. The company is applying its CD33 targeting ARC product candidate lintuzumab-Ac-225 to multiple hematologic indications as CD33 is an antigen that has been found to be expressed in a majority of patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome and 25% to 35% of patients with Multiple Myeloma.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.